Amnis Corporation

Other

Luminex Corporation

Philip J Morrissey

William E Ortyn

David Abraham Basiji

Brian E Hall

Thaddeus C George

Cathleen A Zimmerman

David Joseph Perry

Michael J Seo

Vidya Venkatachalam

Luchuan Liang

Kenneth H Grabstein

Provided are methods for determining and analyzing photometric and morphometric features of small objects, such as cells to, for example, identify different cell states. In particularly, methods are provided for identifying apoptotic cells, and for distinguishing between cells undergoing apoptosis versus necrosis.

Method for imaging and differential analysis of cells

An automated identification of the types of white blood cells in a blood sample facilitates the manual identification of cancerous or other abnormal blood cells in the sample. Classifiers are predetermined for each type of white blood cell and subsequently used to automatically process images of cells in a sample stained with a nuclear dye or stain. The classifiers each comprise a linear weighted combination of morphometric and photometric features previously selected for white blood cells that were identified using monoclonal antibody stains. Red blood cells and excess fluid are removed from a sample being processed upstream of an imaging region of the imaging system. A plurality of different types of images are produced for each cell by the imaging system enabling automated identification of the white blood cells. Images of any cells not thus identified are manually reviewed to detect cancerous or abnormal cells.

Detection of circulating tumor cells using imaging flow cytometry

Multimodal or multispectral images of cells comprising a population of cells are simultaneously collected. Photometric and/or morphometric image features identifiable in the images are used to identify differences between first and second populations of cells. The differences can include changes in a relative percentage of different cell types in each population, or a change in a first type of cell present in the first population of cells and the same type of cell in the second population of cells. The changes may be indicative of a disease state, indicative of a relative effectiveness of a therapy, or indicative of a health of the person from whom the cells populations were obtained.

Blood and cell analysis using an imaging flow cytometer

Photometric and morphometric features derived from multi-mode imagery of cells in flow are used as a cell analyzer to determine if a marker corresponding to a cancer cell or precancerous cell is present in the population of cells imaged. An imaging system simultaneously acquires a plurality of images for each cell passing through the field of view of the imaging system. Acquiring a plurality of different images (i.e., bright field, dark field, and fluorescent images) facilitates the determination of different morphological and morphometric parameters. Simultaneously acquiring the plurality of images enables relatively large populations of cells to be rapidly imaged, so that relatively small numbers of cancer cells in a large population of cells can be detected. Initially, known cancer cells are imaged to enable a marker to be identified. Then, a sample that may include cancer cells is imaged to determine if the marker is present.

Provided are methods for determining and analyzing photometric and morphogenic features of small objects, such as cells to, for example, identify different cell states. In particularly, methods are provided for identifying apoptotic cells, and for distinguishing between cells undergoing apoptosis versus necrosis.

Multimodal/multispectral images of a population of cells are simultaneously collected. Photometric and/or morphometric features identifiable in the images are used to separate the population of cells into a plurality of subpopulations. Where the population of cells includes diseased cells and healthy cells, the images can be separated into a healthy subpopulation, and a diseased subpopulation. Where the population of cells does not include diseased cells, one or more ratios of different cell types in patients not having a disease condition can be compared to the corresponding ratios in patients having the disease condition, enabling the disease condition to be detected. For example, blood cells can be separated into different types based on their images, and an increase in the number of lymphocytes, a phenomenon associated with chronic lymphocytic leukemia, can readily be detected.

Subjects suffering from infectious diseases are treated by direct administration of therapeutically-effective quantities of granulocyte-macrophage colony stimulating factor employed by itself or in conjunction with an antibiotic or a sulfonamide or other immunologically effective therapeutic agents. Homogeneous granulocyte-macrophage colony stimulating factor for use in treatment in bacterial diseases is prepared by recombinant DNA techniques and then purified to homogeneity by reverse phase high-performance liquid chromatography so that it may be safely administered to subject's suffering from infectious diseases.

Growing community of inventors

Bellevue, WA, United States of America

Philip J Morrissey